Y2024 AL101-AMD Clinical Phase 3 IND Approved for Wet Macular Degeneration Treatment

Y2023 Technology transfer of AL101-AMD, a treatment for wet macular degeneration
　　　(Hallym Pharmaceutical/Sangmyung Innovation)
　　　Completed Phase 2a clinical trial for AL101-OME, a treatment for otitis media with effusion

Y2022 Completed Phase 2 clinical trial for AL101-AMD, a treatment for wet macular degeneration
　　　Completed Phase 2a clinical trial for AL101-MASH, a treatment for metabolic syndrome-related
　　　fatty liver disease
　　　Completed Phase 2 clinical trial for AL102-PDT, a treatment for periodontal disease
　　　Development of an antibody conjugated with a photosensitizer (APC) through joint research with
　　　external institutions (selected for a project by the Ministry of SMEs and Startups)

Y2019 ~ Y2021 V.C. funding 8.5 billion KRW

Y2019 Signed a MOU on PASylation technology with XL-protein
　　　Received the Korea Industry Grand Prize in Biotechnology Award from Money Today
　　　Received the Korea KONEX Award for Best Technology by the Korea Exchange

Y2018 Launched sales of Ob-X on home-shopping channels

Y2016 Listed in KONEX

Y2013 ~ Y2016 V.C. funding 12 billion KRW

Y2015 AL101-AMD Phase 2 IND approved

Y2012 Started sales of Ob-X in Korea and overseas

Y2010 Ob-X approved as a functional ingredient with health claim by MFDS

Y2009 Completed Phase 2 clinical trial of AL101-AOB for abdominal obesity

Y2007 Awarded INNO-BIZ certification by the SMBA (Small and Medium Business Administration)

Y2006 Attracted capital from the KDB (Korea Development Bank) for technology development

Y2005 Selected as an 'Excellent Company' by the Korea Technology and Credit Guarantee Agency

Y2004 ~ Y2009 Awarded numerous research grants from the Ministry of Health & Welfare and the SMBA for
　　　developing new drugs

Y2000 Research center was certified

Y1999 Recognized as a start-up with good technology